Abstract: An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.

Abstract: A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.

Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus filovirus immunogen including a consensus Marburgvirus filovirus glycoprotein MARV GP immunogen, a consensus Ebolavirus Sudan filovirus glycoprotein SEBOV GP immunogen and a consensus Ebolavirus Zaire glycoprotein ZEBOV GP immunogen are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against filovirus, particularly Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Method of preventing filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire and methods of treating individuals infected with filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Consensus filovirus proteins are disclosed.

Abstract: A method for treating or reducing the incidence of recurrence of cancer, benign tumors or HPV-associated lesions, including skin cancer, and particularly squamous cell carcinoma (SCC and basal-cell carcinoma, by administering one or more doses of HPV recombinant vaccine to a patient.

Abstract: The invention relates to an influenza viruses hemagglutinin protein as a vaccine antigen against influenza viruses, in particular to a protein being a fragment of H5 hemagglutinin from highly pathogenic avian influenza virus (HPAIV) H5N1 strain, expressed in a bacterial expression system. The protein according to the invention is a potential ingredient of an anti-HPAIV H5N1 vaccine, administered to chickens parenterally or through mucous membranes in the presence of adjuvants. The object of the invention is also a method of obtaining the vaccine protein.

Abstract: An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.

Abstract: The present invention relates to a thermostable freeze dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses multivalent thermostable liquid, powder or cake based rotavirus vaccine formulation prepared using the freeze drying process, such that the said vaccine formulation possess improved heat-stability, easy to use and transport and highly affordable thereby meeting the requirements of developing and low income country's vaccination program. The said freeze dried rotavirus vaccine formulation along with reconstitution buffer is so engineered to be suitable for filling in appropriate packaging containers/ closures so designed such that they reduce the logistics requirement for storage.

Abstract: Synthetic HIV envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in vaccines to provide improved protective immunity against HIV.

Abstract: The present invention relates to a hybrid vaccine for protecting a feline against diseases associated with respiratory diseases. The vaccine commonly includes a feline antigen. Methods for protecting felines against diseases associated with feline gastrointestinal and respiratory diseases, including but not limited to feline calicivirus, feline rhinotracheitis and feline panleukopenia, and methods of producing the feline vaccine are also provided.

Abstract: The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of Helicobacter pylori or a cell lysate thereof, and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject.

Abstract: Provided herein are (1) a method of mixing an aluminum salt-adsorbed immunogen with a monophosphoryl lipid A (MPLA)-containing liposome (L(MPLA)), and (2) the resulting immunogenic composition. The resulting immunogenic composition has an enhanced immunostimulation potency compared with either a composition comprising the uncapsulated immunogen mixed with the L(MPLA) or the aluminum salt-adsorbed immunogen alone.

Abstract: The present invention provides immunostimulatory combinations of TLR ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions.

Abstract: Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-? and/or another agent that promotes expansion of regulatory T cells. In certain aspects, the disclosed process results in improved kidney function and survival rates.

Abstract: The invention relates to methods for treating a Lysosomal storage disease (LSD) in a patient. Kits for use in such methods are also provided.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: Described are methods of treating or preventing cancer in patients by administering Interleukin 6 (IL-6) inhibitor and Interleukin 8 (IL-8) inhibitor, in a concentration ratio range to inhibit the migration of cancer cells.

Abstract: Disclosed is a novel means effective for treatment, metastasis-inhibition, and recurrence-inhibition of human solid cancer. A therapeutic agent for solid cancer according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. Said anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The therapeutic agent of the present invention produces still higher effects by combined use with antagonist or agonist against immune checkpoint molecule, small molecule anticancer agents, or the like. The therapeutic agent is also effective in suppressing recurrence and metastasis of solid cancer.

Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.

Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.

Abstract: A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Abstract: Composition comprising at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of said composition.

Abstract: The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.

Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.

Abstract: Esters prodrugs that cross the blood brain barrier can be ideal drugs for treatment of diseases of the central nervous system because the cerebral spinal fluid contains an abundance of esterases. The prodrug can be hydrolyzed into an active drug and a metabolite such as cholesterol that is known to be non-toxic and is familiar to the central nervous system. This invention describes a modification of the Fischer-Speier or Fischer esterification reaction in which one reagent is lipophilic and the other reagent is hydrophilic. The reaction occurs in a heterogeneous mixture. The preferred catalyst is 1.0 M hydrochloric acid and the preferred solvent is acetone. The presence of ester synthesis was confirmed by the hydroxamic acid-ferric perchlorate reaction. The synthesis can be conducted without chemical scaffolds and without protecting functional groups.

Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.

Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.

Abstract: Provided herein are pharmaceutical compositions comprising an antibiotic encapsulated in liposomes. The lipid membrane component of the liposomes, or portion thereof comprises an unsaturated phospholipid. The antibiotic-to-lipid component weight ratio of the liposomes ranges from about 0.5-to-1 to about 3-to-1. The pharmaceutical compositions in some embodiments also include free antibiotic, in addition to encapsulated antibiotic. Methods for treating bacterial infections, e.g., pulmonary bacterial infections such as nontuberculous mycobacterial infections with the pharmaceutical compositions are also provided.

Abstract: The invention provides novel antibiotic protocells comprising mesoporous nanoparticles encapsulated within a lipid bi- or multilayer. The nanoparticles have pore sizes and surface chemistries that enable facile adsorption and intracellular presentation of antibiotics which are effective in the treatment of a wide variety of bacterial infections, including F. tularensis, B. pseudomallei and P. aeruginosa-related infections. Related pharmaceutical compositions and methods of treatment are also provided.

Abstract: Aptamers consisting of a single stranded nucleic acids having 100 nucleotides or less that specifically binds to tumor initiating cancer cells are described. The aptamers can be identified by screening a large pool of randomly generated aptamers to obtain a discrete set of aptamers that specifically bind to tumor initiating cancer cells, such as those found in brain cancer or glioblastoma. The aptamers can also be linked or complexed with anticancer agents or imaging agents for use in therapy or diagnosis.

Abstract: The invention in some aspects relates to isolated nucleic acids, compositions, and kits useful for identifying adeno-associated viruses in cells. In some aspects, the invention provides kits and methods for producing somatic transgenic animal models using recombinant AAV (rAAV) to an animal having at least one transgene that expresses a small interfering nucleic acid or at least one binding site for a miRNA.

Abstract: A composition for treating cancerous cells in a subject having an immune system includes a virus in the Yatapoxvirus genus having at least one mutation. In one embodiment, the mutation results in suppressed expression of a TNF binding protein by the virus. In another embodiment, the mutation results in suppressed expression of thymidine kinase (“TK”) by the virus. In another embodiment, the mutation arms the virus with a transgene to express a bacterial flagellin. The mutations can be present singly or in combination. Additional aspects include a method of treating cancerous cells with a composition as described herein, and a method of delivering at least one gene to cancerous cells in a subject.

Abstract: Method and Product; For use in the human digestive tract for endoscopic submucosal injection, as an aid in identifying the extent and borders of flat mucosal polyps (neoplasia) and creating a dynamic gastrointestinal tract mucosa lift of the surrounding mucosa for a safe and through snare polypectomy.

Abstract: Disclosed are compositions comprising a plastic polymer core, a shell surrounding the plastic polymer core, a ligand comprising a binding moiety, an enzyme capable of catalyzing the hydrolysis of a target compound, and a contrast agent, as well as methods of use of such compositions.

Abstract: The present invention relates to new combinations of treatments for abnormal dopamine deficiency disorders, and related conditions, comprising deuterated catecholamine derivatives and catechol-O-methyltransferase (COMT) inhibitors.

Abstract: The present invention provides conjugates containing metal binding ligands, as well as nanocarriers prepared from the conjugates.

Abstract: The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents.

Abstract: A method and device for destroying and inhibiting exposure to microbes and infection includes a first element and a second element, and a power source. At least one of the elements includes antimicrobial metal, which, when energized by the power source, produces ions that are lethal to microbes. The device can be incorporated into virtually any useful object. During normal use of the object, electrical communication is established between the two elements, causing current supplied from the power source to flow through the antimicrobial metal. The two elements are configured and arranged to ensure that ions flowing from the antimicrobial metal flow through the region in which it is desired to kill microbes. The antimicrobial metal can be on the surface of the element, incorporated into the material making up the element, or provided in any other way that allows the antimicrobial effect to be achieved.

Abstract: A method of irradiating a work piece may include forming a cutout recessed from a surface of a light guide, positioning the work piece inside the cutout, irradiating a light input surface of the light guide with UV light, and guiding the UV light from within the light guide through recessed surfaces of the cutout to irradiate the work piece. In this way more uniform irradiation of all curable surfaces of a work piece may be achieved, the energy and time consumed during irradiation of the work piece may be reduced thereby lowering operating costs, and the radiation delivery system may be made more compactly, thereby making it more convenient and practical for daily applications.

Abstract: A mobile electronic device storage and charging cabinet includes a body defining therein an accommodation chamber and carriers with individual storage chambers mounted in the accommodation chamber for storing mobile electronic devices individually, a power supply module consisting of a control system and a connector module and mounted in the accommodation chamber with electrical connectors of the connector module respectively electrically connected to storage mobile electronic devices by cables, and a sterilizer consisting of a germicidal lamp set and power drive module and mounted in the body for killing microorganisms, molds, fungi and unicellular algae that are suspended in the air inside the body and adhered to the surfaces of storage mobile electronic devices with ultraviolet light from ultraviolet lamp tubes of the germicidal lamp set subject to the control of the power drive module, achieving optimal disinfection and sterilization effects and protecting the users from health risks.

Abstract: A sanitizer for sanitizing various surfaces including hands, hardware fixtures appliances, countertops, equipment, utensils and more and more specifically to a chemical-free sanitizer, more specifically to an ozone-free sanitizer and yet more specifically to an electronic sanitizer and yet more specifically to an ion source sanitizer. The present invention relates generally to an ion sanitizer including a controller and at least one ion electrode operationally coupled to the controller and the ion electrode includes a plurality of ion sources spaced 6-51 mm apart The ion sanitizer defines a fixture cavity having a plurality of ion sources each include a point directed toward the fixture cavity.

Abstract: An organic waste odor absorbing composition for the absorption of odors resulting from decomposing organic waste is disclosed. The composition comprises dried carbon and/or silica based matter, either natural or synthetic. The carbon-based materials consist of 35% to 85% holocellulose and 8% to 30% lignin. The silica-based materials consist of 40% to 80% silica. The materials may be mechanically sized to allow for adequate airflow and surface area exposure to the organic waste.

Abstract: An automated heat transfer press and method for automated heat transfer pressing provides an electric linear actuator motor that induces an arced translation of a first plate onto a second plate for dye sublimation printing. The arced motion of the first plate enables the first plate to press against the second plate at an angle, rather than a vertical pressing action; whereby adaption to a variously sized and dimensioned substrates is possible. A second link bar adjusts alignment of the second plate with first plate. An electric linear actuator motor manipulates a rod through electrical power. Rod is extended to create linear motion. The rod operatively connects to a hinged arm, applying linear force that causes the hinged arm to displace the first plate at arced motion. A control portion regulates the linear actuator motor to press and release the plates against each other in predetermined temperatures and intervals.

Abstract: A method of connecting a cartridge comprising a fluid composition with a microfluidic delivery system is provided. The method includes the steps of: providing a housing comprising electrical contacts, wherein the electrical contacts of the housing are disposed on a first plane; providing a cartridge comprising a reservoir for containing a fluid composition, a die comprising a nozzle, and electrical contacts that are in electrical communication with the die, wherein the electrical contacts of the cartridge are disposed along a second plane that is parallel with the first plane; and connecting the cartridge with the housing by moving the cartridge in a direction parallel with the second plane toward the housing until the electrical contacts of the cartridge are in electrical communication with the electrical contacts of the housing.

Abstract: A system for delivering a multi-phase fragrance composition comprises a container having a body forming a reservoir and an opening in communication with the reservoir and a multi-phase composition disposed within the reservoir. The multi-phase composition comprises a water phase composition and an oil phase composition and the water phase composition and the oil phase composition are substantially separated. The water phase composition comprises a water phase fragrance and both water and propylene glycol as water phase solvents. The oil phase composition comprises an oil phase fragrance and isopar M as an oil phase solvent. The system further includes a wick in contact with the water phase composition and the oil phase composition and configured to sequentially emit the water phase composition and the oil phase composition.

Abstract: An unheated, essential oil diffuser relies on a pressurized air stream to educt oil from a reservoir, followed by separators including separation chambers and an annular channel. The latter is a long channel having an aspect ratio (L/d) of from about 10 to about 120, for length L and thickness d. Thickness d is effective diameter, also known as hydraulic diameter (4 times c.s. area, divided by “wetted” or exposed perimeter), and may be from about 25 to about 100 thousandths of an inch (0.6 to 2.5 mm) across the thin passage, with a target range of from about 55 to 75 mils (0.7 to 1 mm). This geometry provides laminar flow at Reynolds number values less than a few hundred for virtually its complete distance of from under one inch (25 mm) to over three inches (76 mm).

Abstract: A method of removing a liquid from a container (1) for accommodating an ophthalmic contact lens, in particular a soft contact lens, during transporting the container (1) from a liquid bath (13) to a subsequent processing station (14), the method including the steps of: transporting the container (1) from the liquid bath to the subsequent processing station, generating suction (20), and applying the suction (20) to a bottom (11) of the container (1) during the step of transporting the container (1) from the liquid bath to the subsequent processing station, thereby removing the liquid from the container (1).

Abstract: A medical device in the form of a nonwoven wound dressing includes rotospun fibers including at least one synthetic and bioabsorbable polymer and at least one hydrophilic and/or tissue-adhesive polymer, and a method of producing the medical device including using rotospinning to produce fibers from a fiber raw material including at least one synthetic and bioabsorbable polymer and at least one hydrophilic and/or tissue-adhesive polymer.

Abstract: Systems for managing intimate skin are described. The systems include a cosmetic product that comprises an applicator and a cosmetic composition disposed within the applicator. The cosmetic composition is solid at room temperature, such that some may describe the cosmetic composition as being in a stick form.

Abstract: Absorbent articles comprising topsheet laminates bonded with substantially tackifier-free adhesives, wherein the topsheet laminates comprise morphological treatments.

Abstract: The present invention refers to a composition that is useful as a filler for the correction of soft tissue volume loss, for example for the cosmetic treatment of wrinkles, or for the treatment of disorders such as lipoatrophy or lipodystrophy in general, said composition comprising agarose and hyaluronic acid, or a pharmaceutically acceptable salt thereof. The particular interaction that takes place between the two components makes even high concentrations of agarose injectable and tolerable, said high concentrations being particularly useful for ensuring the duration and stability over time of the aesthetic results that are achievable using this filler.